EU health policy at a turning point: What pharma needs to know for launch, P&MA, and commercial strategy
The EU health policy landscape is shifting fast and the implications for pharma launch planning, pricing and market access (P&MA), and commercial strategy are significant.
With EU Pharmaceutical Legislation reform and the Critical Medicines Act taking shape, companies are facing new questions around launch obligations, supply resilience, procurement, and access strategy.
Join our upcoming webinar, where our EU HTA and Health Policy team is joined by legal and payer experts to discuss the latest EU policy developments and what they mean for pharma companies operating in Europe.
Drawing on recent interviews with senior pharma representatives across companies of varying sizes, market footprints, and portfolio profiles, our panel will explore the opportunities, risks, and strategic choices emerging from this evolving policy landscape.
Key discussion topics:
